Skip to search formSkip to main contentSkip to account menu

ESHAP regimen

Known as: Etoposide-Solumedrol-High Dose Ara-C, Platinol Regimen 
A regimen consisting of etoposide, methylprednisolone, high-dose cytarabine and cisplatin, used to treat relapsed and refractory Hodgkin's and non… 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (3)

Antineoplastic Combined Chemotherapy ProtocolsEtoposidePrednisone
CisplatinCytarabineMethylprednisoloneRefractory Hodgkin Lymphoma

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group
There is no standard treatment for relapsed follicular lymphoma (FL). Although platinum-based combinations are one of the most… 
2018
2018
Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma
Background Salvage chemotherapy is the mainstay for the treatment of relapsed/refractory peripheral T-cell lymphomas (R/R PTCLs… 
2016
2016
Phase II trial of ofatumumab plus ESHAP (O‐ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first‐line chemotherapy
The management of recurrent/refractory (R/R) Hodgkin lymphoma (HL) remains challenging. Previously published data have shown some… 
2015
2015
GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
ABSTRACT Background: Despite multiple published studies reporting result of salvage regimens for relapsed and refractory Hodgkin… 
Review
2010
Review
2010
Efficacy and Safety of Modified Rituximab-ESHAP Therapy for Relapsed/Refractory B-Cell Lymphoma
Abstract Combined therapy of rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin (R-ESHAP) has been one… 
2009
2009
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome
We have read with interest the excellent editorial by Sud and Friedberg about salvage therapy for relapsed or refractory diffuse… 
2008
2008
Predictors for Successful Mobilization of Peripheral Blood Progenitor Cells with ESHAP+G‐CSF in Patients with Pretreated Non‐Hodgkin's Lymphoma
2006
2006
ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
Background The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine… 
1999
1999
Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients.
The purpose was study the feasibility of ESHAP + G-CSF for peripheral blood hematopoietic progenitor cell (PBPC) mobilisation in… 
1998
1998
Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy
High-dose therapy with peripheral blood stem cell (PBSC) support is a frequently used treatment option in younger patients with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)